Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC-Reference-Cited by-同舟云学术

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Published:2019-02-01 Issue:2 Volume:5 Page:195
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Siu Lillian L.¹,Even Caroline²,Mesía Ricard³,Remenar Eva⁴,Daste Amaury⁵,Delord Jean-Pierre⁶,Krauss Jürgen⁷,Saba Nabil F.⁸,Nabell Lisle⁹,Ready Neal E.¹⁰,Braña Irene¹¹,Kotecki Nuria¹²,Zandberg Dan P.¹³,Gilbert Jill¹⁴,Mehanna Hisham¹⁵,Bonomi Marcelo¹⁶,Jarkowski Anthony¹⁷¹⁸,Melillo Giovanni¹⁷,Armstrong Jon M.¹⁹,Wildsmith Sophie²⁰,Fayette Jérôme²¹

Affiliation:

1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

2. Department of Head and Neck Cancer, Gustave Roussy, Villejuif, France

3. Medical Oncology Department, Catalan Institute of Oncology–Badalona, University of Barcelona, IDIBELL, Barcelona, Spain

4. Fej-nyak Állcsont, Rekonstrukciós Plasztikai Sebészeti és Laser Sebészeti Osztály, Országos Onkológiai Intézet, Budapest, Hungary

5. Department of Medical Oncology, Hôpital Saint André, Bordeaux, France

6. Département d’Oncologie Médicale, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

7. Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany

8. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia

9. Department of Medical Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham

10. Department of Medicine, Duke University Medical Center, Durham, North Carolina

11. Medical Oncology Department, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Spain

12. Département de Cancérologie Cervico-Faciale, Centre de Lutte Contre le Cancer–Centre Oscar Lambret, Lille, France

13. University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania

14. Department of Hematology and Oncology, Henry-Joyce Cancer Clinic, Nashville, Tennessee

15. Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, United Kingdom

16. Department of Medical Oncology, The Ohio State University, Columbus, Ohio

17. AstraZeneca, Gaithersburg, Maryland

18. Now with Bristol-Myers Squibb, New Brunswick, New Jersey

19. AstraZeneca, Cambridge, United Kingdom

20. Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom

21. Clinical Oncology, Cancer Center Centre Léon Bérard, University of Lyon, Lyon, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/2/195/17295259/jamaoncology_siu_2018_oi_180088.pdf

Reference37 articles.

1. End points for new agents in induction chemotherapy for locally advanced head and neck cancers.;Monnerat;Ann Oncol,2002

2. Optimal treatment for recurrent/metastatic head and neck cancer.;Vermorken;Ann Oncol,2010

3. Gefitinib, methotrexate and methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.;Kushwaha;Cancer Biol Ther,2015

4. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck;Stewart;J Clin Oncol,2009

5. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.;Vermorken;J Clin Oncol,2007

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Saliva as a potential non-invasive liquid biopsy for early and easy diagnosis/prognosis of head and neck cancer;Translational Oncology;2024-02

2. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives;Immunotherapy;2024-02

3. A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ALARM” study;Cancer Medicine;2024-01-21

4. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis;Frontiers in Immunology;2024-01-17

5. Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives;Frontiers in Oncology;2024-01-04